On March 2, 2023 Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, reported participation in the following investor and scientific conferences in March (Press release, Immunic Therapeutics, MAR 2, 2023, View Source [SID1234628097])
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
March 9: BioCapital Europe. Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic, will present a company overview at this conference in Amsterdam on March 9, 2023, at 3:20 pm CET as part of the Listed Healthcare Track. Specific details regarding webcast and replay information will be published on the "Events and Presentations" section of Immunic’s website at: View Source, once they are available.
March 17-21: 2023 American Academy of Dermatology (AAD) Annual Meeting. Andreas Muehler, M.D., Chief Medical Officer of Immunic, will attend this conference in New Orleans, Louisiana.
March 28-31: 32nd Annual Meeting of the Society for Virology. Members of Immunic’s preclinical team and its collaboration partners have been accepted to present three posters at this conference in Ulm, Germany. Specific details for the oral and poster presentations will be published on the "Events and Presentations" section of Immunic’s website at: ir.imux.com/events-and-presentations, once they are available.
Poster Presentation: Preclinical Development of Optimized DHODH Inhibitors as Broad-Spectrum Antivirals for the Treatment of Respiratory Virus Infections
Presenting Author: Dr. Alexandra Herrmann, Program Manager Virology, Immunic
Poster Presentation: Characterization of an MPXV Outbreak in Franconia (Bavaria, Germany) and Antiviral Testing of Patient Isolates
Presenting Author: Dr. Arne Cordsmeier, Institute for Clinical and Molecular Virology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany (co-authored by Immunic)
Oral Presentation: Selective Small Molecules Directed to Nuclear Receptor RORγ Isoform 1 Exhibit a Broad Antiviral Potential Through Metabolic Restriction of Virus Replication
Presenting Author: Dr. Friedrich Hahn, Institute for Clinical and Molecular Virology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany (co-authored by Immunic)